Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,599.96
(
0.00%
)
US TECH 100
29,689.60
(
-0.07%
)
Dow Jones
51,078.88
(
0.00%
)
Brent Oil
93.38
(
-2.70%
)
Bitcoin
69,088.79
(
-3.19%
)
News Focus
News Focus
Post# of 23755
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Aladdin Sane

Send PM Follow Ignore
Followers 19
Posts 1201
Boards Moderated 0
Alias Born 08/28/2020

Aladdin Sane

Re: None

Thursday, 12/28/2023 11:22:10 PM

Thursday, December 28, 2023 11:22:10 PM

Post# of 23755
Per Chris's analysis of Biotech growth 2024... companies with compelling clinical data and closest to market with a first in class therapeutic drug will be the prime candidates for funding or IPO. Vyome with VB-1953 fits that description perfectly. (A Reverse Merger would be the same as an IPO as it is a more expedient and cost-efficient method to go public).
Bullish
Bullish
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote